This article on Marketwatch is really telling. The US biotech market is completely unaware of CU6. Imagine what happens when they finally notice.
“Given that many pharma companies missed the … boat over the last five years, they are beginning to see that being competitive in targeted oncology will require radiopharm programs in their portfolio,” Raymond James analyst Rahul Sarugaser said.
Also on Wednesday, Oppenheimer analysts said Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain.”
Oppenheimer reiterated an outperform rating on Fusion Pharmaceuticals and said the company is the “last available target to serve as a foundation for a large-pharma to build a presence in targeted radiopharmaceuticals.”
https://www.marketwatch.com/story/f...l-company-as-potential-merger-target-e50a6cfa
Research/Valuation, page-56
-
- There are more pages in this discussion • 608 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.35 |
Change
0.200(2.80%) |
Mkt cap ! $2.353B | |||
| Open | High | Low | Value | Volume |
| $7.22 | $7.58 | $7.17 | $8.142M | 1.098M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3007 | $7.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.35 | 2304 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |